Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe page now states the study has 199 locations and removes several previously listed sites. The eligibility language is refined to specify TP53 wild-type status by central NGS for histologically confirmed endometrial cancer.SummaryDifference0.5%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision metadata updated from v3.6.4 to v3.6.5, indicating a newer build of the page. No study data or visible content appears to be affected.SummaryDifference0.0%

- Check43 days agoChange DetectedA new page revision tag indicates the study page was updated from version v3.6.3 to v3.6.4. This appears to be a minor metadata update rather than a substantive change to the study content.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision: v3.6.3 was recorded in the page history, replacing v3.6.2. This is a minor version update and does not change the study details or user-visible content.SummaryDifference0.0%

- Check71 days agoChange DetectedThe revision history now displays v3.6.2 as the current page version, replacing the previous v3.6.0. This indicates the page content has been refreshed to a newer version.SummaryDifference0.0%

- Check86 days agoChange DetectedThe study page now notes that recruitment is closed and no longer accepting participants.SummaryDifference0.2%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.